Human Microbiome Manufacturing Services Market

The human microbiome manufacturing services market is projected to reach USD 0.27 billion by 2031 from USD 0.11 billion in 2025, at a CAGR of 16.7% during the forecast period.

Lonza (Switzerland), Evonik (Germany), Lallemand Inc. (Canada), Cerbios-Pharma SA (Canada), List Biological Labs, Inc. (US), Elise Biopharma (US), Eurofins Scientific (Luxembourg), and Charles River Laboratories (US) are the key players in this market.

These market players have implemented various strategies, including product launches, acquisitions, agreements, collaborations, and expansions, to strengthen their market positions. In September 2024, Lonza expanded its microbial manufacturing capacity in Germany, scaling up its ability to produce live biotherapeutic products (LBPs). This expansion enhances Lonza's ability to meet the rising demand for clinical- and commercial-scale microbiome and biologics manufacturing.

To know about the assumptions considered for the study download the pdf brochure

Lonza (Switzerland)

Is a global CDMO that specializes in microbial and live biotherapeutic product (LBP) manufacturing. It offers comprehensive services, including strain development, GMP fermentation, downstream processing, analytical testing, and fill-finish for microbiome therapeutics. Lonza has increased its manufacturing capacity with advanced bioreactors, automated processing, and dedicated LBP suites. Its worldwide network, regulatory expertise, and collaborations with both emerging and established biopharma companies make it a leading provider in human microbiome manufacturing services.

Evonik (Germany)

Offers integrated CDMO services in bioprocess R&D and formulation. The company highlights precision fermentation, strain engineering, and advanced delivery technologies for probiotics, postbiotics, and live microbial therapeutics. With multiple GMP-compliant facilities and investments in biomanufacturing platforms, the company supports global microbiome product development and strengthens its role in the manufacturing services market.

Eurofins Scientific (Luxembourg)

Specializes in providing analytical and bioanalytical services for microbiome product development. It offers microbiology testing, genomic analysis, strain characterization, metagenomics, microbial safety, and GMP-compliant QC/QA support. Through collaborations with biopharma and microbiome vendors, Eurofins maintains regulatory compliance and stability. Its global laboratory network and analytical capabilities make it an essential partner for microbiome production and commercialization processes.

Market Ranking

The human microbiome manufacturing services market is moderately consolidated, with key CDMOs shaping capabilities and capacity. Leading players include Lonza (Switzerland), Evonik Industries (Germany), and Eurofins Scientific (Luxembourg). Lonza provides comprehensive solutions for large-scale GMP fermentation, downstream processing, analytical services, and regulatory expertise in the development of live biotherapeutics. Evonik focuses on precision fermentation, strain engineering, and formulation technologies for probiotics, postbiotics, and microbial therapeutics. Eurofins provides critical analytical support, including metagenomics, strain characterization, and QC/QA testing. Together, these companies drive innovation, expand GMP facilities, and collaborate with biopharma partners.

Related Reports:

Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease)-Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441